Rrd Logo (Rrd Group Logo)
Signifor Lar Kit
Product Images NDC 55292-143
24 FDA label images from Recordati Rare Diseases, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Signifor Lar (NDC 55292-143). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Recordati Rare Diseases, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Signifor Lar 10mg Crt (Signiforlar 10mg Crt)
Signifor LAR 10 mg kit for injectable suspension containing pasireotide, intended for intramuscular use. The packaging includes full prescribing information instructions and lists inactive ingredients and storage instructions. Labeler is Recordati Rare Diseases, Inc. The label shows the product name, strength, dosage form, and regulatory information including NDC and barcode.*
Signifor Lar 20 mg Crt (Signiforlar 20mg Crt)
Signifor LAR (pasireotide) 20 mg kit packaging label for injectable suspension for intramuscular use. The label includes dosage strength, storage instructions to refrigerate at 2°C to 8°C and not to freeze, labeler as Recordati Rare Diseases, Inc., and manufacturing details from Switzerland and The Netherlands. The label notes single use and contains a barcode.*
Signifor Lar 30mg Crt (Signiforlar 30mg Crt)
Signifor LAR 30 mg kit for Injectable Suspension for Intramuscular Use. The package includes prescribing and usage instructions, listing pasireotide pamoate equivalent to 30 mg base as the active ingredient. It details inactive ingredients and instructions to refrigerate between 2°C to 8°C (36°F to 46°F) and not freeze. Manufactured by Novartis Pharma AG, Basel, Switzerland, with prefilled syringes by Abbott Biologicals B.V., the kit is distributed by Recordati Rare Diseases Inc.*
Signifor Lar 40mg Crt (Signiforlar 40mg Crt)
Signifor LAR (pasireotide) 40 mg kit for injectable suspension, for intramuscular use. The label shows the product name, dosing strength, and directions that it is for single use only. It includes detailed ingredient information, storage instructions to refrigerate at 2°C to 8°C, and manufacturer and distributor details. The kit is labeled as prescription only and manufactured by Novartis Pharma AG with distribution by Recordati Rare Diseases, Inc.*
Signifor Lar 60mg Crt (Signiforlar 60mg Crt)
Signifor LAR (pasireotide) injectable suspension kit for intramuscular use. The packaging indicates a 60 mg strength with detailed inactive ingredients and diluent contents listed. Manufacturer information includes Novartis Pharma AG for vials, Abbott Biologicals B.V. for syringes, and distribution by Recordati Rare Diseases, Inc. The label advises refrigeration between 26C to 86C and notes the product is for single use only.*
Structural Formula (Signiforlar 01)
Chemical structure diagrams showing molecular formulas of two compounds. The left structure depicts a complex peptide molecule with multiple rings and amide bonds, consistent with the active ingredient pasireotide. The right structure features a smaller molecule with multiple aromatic rings and hydroxyl and carboxyl functional groups.*
Figure 2. Mean Fasting Plasma Glucose (mg/dl) By Visit In The Study Of Patients With Acromegaly Naïve To Drug Therapy* (Signiforlar 02)
A line graph comparing glucose levels (mg/dL) over 12 months between Signifor LAR and an active comparator. The x-axis indicates time points in months (baseline, 3, 6, 9, 12), with sample sizes noted below each. The y-axis shows glucose levels ranging from 70 to 140 mg/dL. Signifor LAR shows a higher glucose trend compared to the active comparator.*
Included In The Injection Kit: (Signiforlar 03)
An instructional diagram showing components of the Signifor LAR kit by Recordati Rare Diseases, Inc. It includes a vial labeled 'a,' a syringe labeled 'b,' a tray or holder labeled 'c,' and a needle device in a protective case labeled 'd.' The image illustrates the kit parts included for drug administration preparation.*
Step 1 (Signiforlar 04)
An illustration of a circular timer or clock face showing a 30-minute interval, with half the circle shaded and the other half in white, depicting a 30-minute duration.*
Step 2 (Signiforlar 05)
An instructional illustration showing a vial with a rubber stopper and a protective cap being lifted upward off the vial, indicated by a bold arrow pointing away from the vial.*
Remove The Lid Film Of The Vial Adapter Packaging, But Do Not Remove The Vial Adapter From Its Packaging. (Signiforlar 06)
An instructional illustration showing a hand pressing down on a vial or device part, with an arrow indicating a downward motion and an ear symbol nearby, suggesting a sound or click is heard during the action.*
Lift The Packaging Off The Vial Adapter With A Vertical Movement. (Signiforlar 07)
An instructional illustration showing two hands: one hand removing a protective cap from a vial by pulling it upward, and the other hand holding the vial. This diagram likely demonstrates a step for preparing the Signifor LAR kit for use.*
Step 3 (Signiforlar 08)
An instructional illustration showing the preparation of Signifor LAR pasireotide injection. The image depicts a hand attaching or injecting a component into a vial with an upward arrow indicating removal of a cap and a downward arrow with a twisting motion indicating insertion or securing of the syringe or injector into the vial.*
Slowly Push The Plunger All The Way Down To Transfer All The Diluent Solution In The Vial. (Signiforlar 09)
An instructional diagram showing a hand holding a vial while a syringe is being inserted into it. The arrow indicates downward movement of the syringe into the vial, suggesting a preparation step for injection or medication reconstitution.*
Step 4 (Signiforlar 10)
An instructional illustration showing a hand holding a syringe-like device with a needle cap being removed or adjusted, indicated by a double-headed arrow pointing left and right. The image likely demonstrates part of the preparation or administration process for Signifor LAR pasireotide kit.*
Step 5 (Signiforlar 11)
An instructional illustration showing a hand holding a syringe with a vial or cartridge attached at the top. An arrow points downward at the bottom of the syringe, indicating a step in the preparation or administration process of the product.*
Unscrew The Syringe From The Vial Adapter. (Signiforlar 12)
An instructional illustration showing two hands preparing an injection device. One hand is removing a cap from a vial, and the other hand is holding a syringe or pen injector, indicating assembly or medication preparation steps.*
Step 6 (Signiforlar 13)
An instructional illustration showing hands preparing an injection. One hand is holding a syringe while the other hand removes a protective cap from a needle or vial, indicated by downward and rotational arrows for proper handling.*
Pull The Protective Cover Straight Off The Needle. (Signiforlar 14)
An instructional illustration showing hands preparing a syringe with a needle, including removing a cap and the appearance of a droplet at the needle tip, indicating proper priming technique. The image is associated with Signifor LAR pasireotide kit usage instructions.*
Step 7 (Signiforlar 15)
An instructional diagram showing injection sites for Signifor LAR on the buttocks. It instructs to inject at a 90-degree angle, indicating two possible sites, one on each buttock, highlighted with arrows and circles.*
Step 8 (Signiforlar 16)
Instructional diagram showing the preparation of an injection using a syringe and vial adapter. Step A depicts removing a protective cover by pulling it upwards; Step B shows inserting the syringe into the vial adapter by pressing downwards. The third image indicates a sound symbol near the syringe, illustrating proper connection or readiness to inject.*
Figure 3: Mean Gh (mcg/l) Levels By Visit In Drug Naïve Patient Study* (Signiforlar 17)
A line graph comparing mean growth hormone (GH) levels (µg/L) over 12 months between Signifor LAR and an active comparator. The x-axis represents months (0, 3, 6, 9, 12), and the y-axis shows mean GH levels. Two lines, one for Signifor LAR (solid circles) and one for the active comparator (dashed squares), display a decline in GH levels over time.*
Figure 4: Mean Standardized Igf-1 Levels* By Visit In Drug Naïve Patient Study** (Signiforlar 18)
A line graph comparing the mean value of standardized IGF-1 over a 12-month period between Signifor LAR and an active comparator. The x-axis shows months (0, 3, 6, 9, 12) with sample sizes listed, and the y-axis shows mean IGF-1 values ranging from 1.0 to 3.5. Two lines represent Signifor LAR and the active comparator, depicting changes in IGF-1 levels over time.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
